Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
REDWOOD CITY, Calif., Jan. 11, 2021 Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that they have signed a non-exclusive commercial agreement with Bruker Corporation, one of the world’s leading analytical instrumentation companies. This agreement will enable Seer to market the timsTOF Pro mass spectrometer system together with its Proteograph Product Suite. The combined product offering provides customers with a complete and scalable workflow for unbiased, deep, rapid and large-scale proteomics – making proteomics more accessible to a broader range of customers, including those interested in adding proteomics to their genomics and multi-omics studies.